

Image source: The Motley Fool.DATEMay 6, 2026, 5 p.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Carrie Eglinton MannerChief Financial Officer — Kenneth J. McGrathTAKEAWAYSTotal Revenue -- $27.9 million, representing a 4% sequential increase.Diagnostics Segment Revenue -- $16.9 million, up 12% from the prior quarter, with a balanced split between U.S. and international markets.Sample Management Solutions Revenue -- $9.1 million, remaining flat sequentially.GAAP Gross Margin ...
Das Diagnostikunternehmen stärkt Aktionärswerte durch ein zweijähriges Rückkaufprogramm bei gleichzeitiger Produkterweiterung im Bereich molekularer Diagnostik. OraSure Technologies hat ein Aktienr...
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows:
OraSure Technologies Acquires Sherlock Biosciences
BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:
BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure’s Board of Directors currently has seven members.